Tassos Gianakakos
Chief Executive Officer bij MYOKARDIA, INC.
Vermogen: 117 331 $ op 31-03-2024
Profiel
Momenteel bekleedt Anastasios E. Gianakakos de functie van Chief Executive Officer voor MyoKardia, Inc. Hij zit ook in de raad van bestuur van LianBio. In het verleden was de heer Gianakakos President & Senior VP-Business Development bij Codexis, Inc., Procesingenieur bij Merck & Co, Inc., Directeur -Business Development bij Maxygen, Inc. en Chief Business Officer & Senior Vice President bij MAP Pharmaceuticals LLC. Hij behaalde zijn doctoraal aan het Massachusetts Institute of Technology, zijn doctoraal aan de Northwestern University en zijn MBA aan de Harvard Business School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
LIANBIO
0.35% | 15-02-2024 | 363 253 ( 0.35% ) | 117 331 $ | 31-03-2024 |
Actieve functies van Tassos Gianakakos
| Bedrijven | Functie | Begin |
|---|---|---|
| MYOKARDIA, INC. | Chief Executive Officer | 01-10-2013 |
| LIANBIO | Director/Board Member | 01-08-2020 |
Prolaio, Inc.
 Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | President | - |
Eerdere bekende functies van Tassos Gianakakos
| Bedrijven | Functie | Einde |
|---|---|---|
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Corporate Officer/Principal | 01-03-2013 |
| MERCK & CO., INC. | Chief Tech/Sci/R&D Officer | 01-01-1997 |
| CODEXIS, INC. | President | - |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
Opleiding van Tassos Gianakakos
| Massachusetts Institute of Technology | Undergraduate Degree |
| Northwestern University | Graduate Degree |
| Harvard Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| CODEXIS, INC. | Process Industries |
| LIANBIO | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Health Technology |
